Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 6NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neuroblastoma 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

daratumumab 3Dexamethasone 3Bortezomib 2sodium thiosulfate 1pomalidomide 1pembrolizumab 1etoposide phosphate 1darlin protein, Dictyostelium 1bosutinib 1Thalidomide 1Restraint, Physical 1Pemetrexed 1Mitoxantrone 1Lenalidomide 1Gemtuzumab 1Etoposide 1Daunorubicin 1Cytarabine 1Crizotinib 1Cisplatin 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Has announcements × Crizotinib × Clear all
NCT00939770 2020-06-09

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Children's Oncology Group

Phase 1/2 Completed
122 enrolled 24 charts 2 FDA
CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡